Pharmacological therapies for acute respiratory distress syndrome

Current Opinion in Critical Care

Volumn 20, Issue 1, 2014, Pages 113-121

  Spieth, Peter Markus ^a   Zhang, Haibo ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

acute lung injury; Icu; nonventilation

Indexed keywords

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; CRITICAL ILLNESS; FEMALE; FLUID THERAPY; GENETIC THERAPY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPNOTICS AND SEDATIVES; MALE; NEUROMUSCULAR BLOCKING AGENTS; NUTRITION THERAPY; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, ADULT; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84895068019     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0000000000000056     Document Type: Review

References (95)

1. Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. J Clin Invest 2012; 122:2731-2740.
2. Phua J, Badia JR, Adhikari NK, et al. Has mortality from acute respiratory distress syndrome decreased over time?: a systematic review. Am J Respir Crit Care Med 2009; 179:220-227.
3. Tremblay LN, Slutsky AS. Ventilator-induced lung injury: from the bench to the bedside. Intensive Care Med 2006; 32:24-33.
4. Arroliga A, Frutos-Vivar F, Hall J, et al., International Mechanical Ventilation Study G. Use of sedatives and neuromuscular blockers in a cohort of patients receiving mechanical ventilation. Chest 2005; 128:496-506.
5. Hraiech S, Forel JM, Papazian L. The role of neuromuscular blockers in ARDS: benefits and risks. Curr Opin Crit Care 2012; 18:495-502.
6. Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010; 363:1107-1116.
7. Slutsky AS. Neuromuscular blocking agents in ARDS. N Engl J Med 2010; 363:1176-1180.
8. Bifulco M, Malfitano AM, Marasco G. Potential therapeutic role of statins in neurological disorders. Expert Rev Neurother 2008; 8:827-837.
9. Mach F. Statins as immunomodulators. Transpl Immunol 2002; 9:197-200.
10. Shimabukuro-Vornhagen A, Glossmann J, Liebig T, et al. The use of statins in hematopoietic stem cell transplantation. Curr Stem Cell Res Ther 2009; 4:260-265.
11. De Loecker I, Preiser JC. Statins in the critically ill. Ann Intensive Care 2012; 2:19.
12. Altintas ND, Atilla P, Iskit AB, Topeli A. Long-term simvastatin attenuates lung injury and oxidative stress in murine acute lung injury models induced by oleic acid and endotoxin. Respir Care 2011; 56:1156-1163.
13. Cronstein BN, Kimmel SC, Levin RI, et al. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci U S A 1992; 89:9991-9995.
14. Cronstein BN, Kimmel SC, Levin RI, et al. Corticosteroids are transcriptional regulators of acute inflammation. Trans Assoc Am Physicians 1992; 105:25- 35.
15. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids: new mechanisms for old drugs. N Engl J Med 2005; 353:1711-1723.
16. Annane D, Sebille V, Bellissant E, Ger-Inf-05 Study G. Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med 2006; 34:22-30.
17. Tang BM, Craig JC, Eslick GD, et al. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and metaanalysis. Crit Care Med 2009; 37:1594-1603.
18. Liu L, Wang YX, Zhou J, et al. Rapid nongenomic inhibitory effects of glucocorticoids on human neutrophil degranulation. Inflamm Res 2005; 54:37-41.
19. Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008; 4:525-533.
20. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003; 348:727-734.
21. Thompson BT. Corticosteroids for ARDS. Minerva Anestesiol 2010; 76:441-447.
22. Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med 2003; 31:S213-220.
23. Bastarache JA, Wang L, Geiser T, et al. The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor. Thorax 2007; 62:608-616.
24. Ware LB, Matthay MA, Parsons PE, et al., National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 2007; 35:1821-1828.
25. Afshari A, Wetterslev J, Brok J, Moller AM. Antithrombin III for critically ill patients. Cochrane Database Syst Rev 2008; CD005370.
26. Liu KD, Levitt J, Zhuo H, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 2008; 178:618- 623.
27. Sebag SC, Bastarache JA, Ware LB. Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndrome. Curr Pharm Biotechnol 2011; 12:1481-1496.
28. Morris PE, Steingrub JS, Huang BY, et al. A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome. BMC Pulm Med 2012; 12:5.
29. Spragg RG, Lewis JF, Walmrath HD, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med 2004; 351:884-892.
30. Spragg RG, Taut FJ, Lewis JF, et al. Recombinant surfactant protein C-based surfactant for patients with severe direct lung injury. Am J Respir Crit Care Med 2011; 183:1055-1061.
31. Davidson WJ, Dorscheid D, Spragg R, et al. Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a meta-Analysis. Crit Care 2006; 10:R41.
32. Adhikari N, Burns KE, Meade MO. Pharmacologic therapies for adults with acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst Rev 2004; CD004477.
33. Taut FJ, Rippin G, Schenk P, et al. A search for subgroups of patients with ARDS who may benefit from surfactant replacement therapy: a pooled analysis of five studies with recombinant surfactant protein-C surfactant (Venticute). Chest 2008; 134:724-732.
34. Zhang LN, Sun JP, Xue XY, Wang JX. Exogenous pulmonary surfactant for acute respiratory distress syndrome in adults: a systematic review and metaanalysis. Exp Ther Med 2013; 5:237-242.
35. Gregory TJ, Steinberg KP, Spragg R, et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997; 155:1309-1315.
36. Willson DF, Thomas NJ, Markovitz BP, et al. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. J Am Med Assoc 2005; 293:470-476.
37. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000; 342:1334-1349.
38. Sakr Y, Vincent JL, Reinhart K, et al. Sepsis occurrence in acutely ill patients I: high tidal volume and positive fluid balance are associated with worse outcome in acute lung injury. Chest 2005; 128:3098-3108.
39. Wiedemann HP, Wheeler AP, Bernard GR, et al., National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354:2564-2575.
40. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580-637.
41. Finfer S, Bellomo R, Boyce N, et al., Safe Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350:2247-2256.
42. Bulger EM, May S, Kerby JD, et al. Out-of-hospital hypertonic resuscitation after traumatic hypovolemic shock: a randomized, placebo controlled trial. Ann Surg 2011; 253:431-441.
43. Perkins GD, McAuley DF, Thickett DR, Gao F. The beta-Agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med 2006; 173:281-287.
44. Mehta D, Bhattacharya J, Matthay MA, Malik AB. Integrated control of lung fluid balance. Am J Physiol Lung Cell Mol Physiol; 287:L1081-L1090.
45. Gao Smith F, Perkins GD, Gates S, et al., BALTI-2 Study Investigators. Effect of intravenous beta-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet 2012; 379:229-235
46. Matthay MA, Brower RG, Carson S, et al. Randomized, placebo-controlled clinical trial of an aerosolized beta(2)- agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011; 184:561-568.
47. Victorino GP, Newton CR, Curran B. Effect of angiotensin II on microvascular permeability. J Surg Res 2002; 104:77-81.
48. Kiely DG, Cargill RI, Wheeldon NM, et al. Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale. Cardiovasc Res 1997; 33:201-208.
49. Xu ZH, Shimakura K, Yamamoto T, et al. Pulmonary edema induced by angiotensin I in rats. Jpn J Pharmacol 1998; 76:51-56.
50. Yamamoto T, Wang L, Shimakura K, et al. Angiotensin II-induced pulmonary edema in a rabbit model. Jpn J Pharmacol 1997; 73:33-40.
51. Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005; 436:112-116.
52. Rossaint R, Falke KJ, Lopez F, et al. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993; 328:399-405.
53. Dellinger RP, Zimmerman JL, Taylor RW, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med 1998; 26:15-23.
54. Francoe M, Troncy E, Blaise G. Inhaled nitric oxide: technical aspects of administration and monitoring. Crit Care Med 1998; 26:782-796.
55. Lundin S, Mang H, Smithies M, et al. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. The European Study Group of Inhaled Nitric Oxide. Intensive Care Med 1999; 25:911-919.
56. Michael JR, Barton RG, Saffle JR, et al. Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS. Am J Respir Crit Care Med 1998; 157:1372-1380.
57. Taylor RW, Zimmerman JL, Dellinger RP, et al., Inhaled Nitric Oxide in ARDS Study Group. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. J Am Med Assoc 2004; 291:1603-1609.
58. Troncy E, Collet JP, Shapiro S, et al. Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study. Am J Respir Crit Care Med 1998; 157:1483-1488.
59. Afshari A, Brok J, Moller AM, Wetterslev J. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) and acute lung injury in children and adults. Cochrane Database Syst Rev 2010; CD002787.
60. Afshari A, Brok J, Moller AM, Wetterslev J. Inhaled nitric oxide for acute respiratory distress syndrome and acute lung injury in adults and children: a systematic review with meta-Analysis and trial sequential analysis. Anesth Analg 2011; 112:1411-1421.
61. Adhikari NK, Burns KE, Friedrich JO, et al. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-Analysis. Br Med J 2007; 334:779.
62. Australia, New Zealand Extracorporeal Membrane Oxygenation Influenza Investigators. Davies A, Jones D, Bailey M, et al. Extracorporeal membrane oxygenation for 2009 influenza A (H1N1) acute respiratory distress syndrome. J Am Med Assoc 2009; 302:1888-1895.
63. Hsu CW, Lee DL, Lin SL, et al. The initial response to inhaled nitric oxide treatment for intensive care unit patients with acute respiratory distress syndrome. Respiration 2008; 75:288-295.
64. Gerlach H, Keh D, Semmerow A, et al. Dose-response characteristics during long-term inhalation of nitric oxide in patients with severe acute respiratory distress syndrome: a prospective, randomized, controlled study. Am J Respir Crit Care Med 2003; 167:1008-1015.
65. Papazian L, Bregeon F, Gaillat F, et al. Respective and combined effects of prone position and inhaled nitric oxide in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1998; 157:580-585.
66. Mehta S, MacDonald R, Hallett DC, et al. Acute oxygenation response to inhaled nitric oxide when combined with high-frequency oscillatory ventilation in adults with acute respiratory distress syndrome. Crit Care Med 2003; 31:383-389.
67. Gallart L, Lu Q, Puybasset L, et al. Intravenous almitrine combined with inhaled nitric oxide for acute respiratory distress syndrome. The NO Almitrine Study Group. Am J Respir Crit Care Med 1998; 158:1770-1777.
68. Reyes A, Roca J, Rodriguez-Roisin R, et al. Effect of almitrine on ventilationperfusion distribution in adult respiratory distress syndrome. Am Rev Respir Dis 1988; 137:1062-1067.
69. B'Chir A, Mebazaa A, Losser MR, et al. Intravenous almitrine bismesylate reversibly induces lactic acidosis and hepatic dysfunction in patients with acute lung injury. Anesthesiology 1998; 89:823-830.
70. Afshari A, Brok J, Moller AM, Wetterslev J. Aerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Cochrane Database Syst Rev 2010; CD007733.
71. Shapiro H, Kagan I, Shalita-Chesner M, et al. Inhaled aerosolized insulin: a 'topical' anti-inflammatory treatment for acute lung injury and respiratory distress syndrome? Inflammation 2010; 33:315-319.
72. Yilmaz S, Daglioglu K, Yildizdas D, et al. The effectiveness of heliox in acute respiratory distress syndrome. Ann Thorac Med 2013; 8:46-52.
73. Hughes CG, McGrane S, Pandharipande PP. Sedation in the intensive care setting. Clin Pharmacol 2012; 4:53-63.
74. McGrane S, Pandharipande PP. Sedation in the intensive care unit. Minerva Anestesiol 2012; 78:369-380.
75. Jakob SM, Ruokonen E, Grounds RM, et al., Dexmedetomidine for Long-Term Sedation Investigators. Dexmedetomidine vs. midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. J Am Med Assoc 2012; 307:1151-1160.
76. Devabhakthuni S, Armahizer MJ, Dasta JF, Kane-Gill SL. Analgosedation: a paradigm shift in intensive care unit sedation practice. Ann Pharmacother 2012; 46:530-540.
77. Ishida R, Nikai T, Hashimoto T, et al. Intravenous infusion of remifentanil induces transient withdrawal hyperalgesia depending on administration duration in rats. Anesth Analg 2012; 114:224-229.
78. Petrenko AB, Ishii H, Kohno T, Baba H. When similar is not alike: decreased sensory thresholds after intravenous infusion of remifentanil may not be remifentanil-induced hyperalgesia. Anesth Analg 2012; 115:977.
79. Soukup J, Scharff K, Kubosch K, et al. State of the art: sedation concepts with volatile anesthetics in critically Ill patients. J Crit Care 2009; 24:535-544.
80. Mesnil M, Capdevila X, Bringuier S, et al. Long-term sedation in intensive care unit: a randomized comparison between inhaled sevoflurane and intravenous propofol or midazolam. Intensive Care Med 2011; 37:933-941.
81. Soukup J, Selle A, Wienke A, et al. Efficiency and safety of inhalative sedation with sevoflurane in comparison to an intravenous sedation concept with propofol in intensive care patients: study protocol for a randomized controlled trial. Trials 2012; 13:135.
82. Rice TW, Wheeler AP, Thompson BT, et al. Initial trophic vs. full enteral feeding in patients with acute lung injury: the EDEN randomized trial. J Am Med Assoc 2012; 307:795-803.
83. Doig GS, Simpson F, Sweetman EA, et al. Early parenteral nutrition in critically ill patients with short-term relative contraindications to early enteral nutrition: a randomized controlled trial. J Am Med Assoc 2013; 309:2130-2138.
84. Bastarache JA, Ware LB, Girard TD, et al. Markers of inflammation and coagulation may be modulated by enteral feeding strategy. JPEN J Parenter Enteral Nutr 2012; 36:732-740.
85. Needham DM, Dinglas VD, Morris PE, et al. Physical and cognitive performance of acute lung injury patients one year after initial trophic vs. full enteral feeding: EDEN trial follow-up. Am J Respir Crit Care Med 2013; 188:567- 576.
86. Needham DM, Dinglas VD, Bienvenu OJ, et al. One year outcomes in patients with acute lung injury randomised to initial trophic or full enteral feeding: prospective follow-up of EDEN randomised trial. Br Med J 2013; 346:f1532.
87. Casaer MP, Mesotten D, Hermans G, et al. Early versus late parenteral nutrition in critically ill adults. N Engl J Med 2011; 365:506-517.
88. Marik PE, Zaloga GP. Immunonutrition in critically ill patients: a systematic review and analysis of the literature. Intensive Care Med 2008; 34:1980- 1990.
89. Heyland D, Muscedere J, Wischmeyer PE, et al., Canadian Critical Care Trials Group. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med 2013; 368:1489-1497.
90. Pontes-Arruda A, Demichele S, Seth A, Singer P. The use of an inflammationmodulating diet in patients with acute lung injury or acute respiratory distress syndrome: a meta-Analysis of outcome data. JPEN J Parenter Enteral Nutr 2008; 32:596-605.
91. Rice TW, Wheeler AP, Thompson BT, et al., NIH NHLBI Acute Respiratory Distress Syndrome Network of Investigators. Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury. J Am Med Assoc 2011; 306:1574-1581.
92. Xu F, Hu Y, Zhou J, Wang X. Mesenchymal stem cells in acute lung injury: are they ready for translational medicine? J Cell Mol Med 2013; 7:927- 935.
93. Wang YY, Li XZ, Wang LB. Therapeutic implications of mesenchymal stem cells in acute lung injury/acute respiratory distress syndrome. Stem Cell Res Ther 2013; 4:45.
94. Devaney J, Contreras M, Laffey JG. Clinical review: gene-based therapies for ALI/ARDS: where are we now? Crit Care 2011; 15:224.
95. Lin X, Dean DA. Gene therapy for ALI/ARDS. Crit Care Clin 2011; 27:705- 718.